空间转录组揭示了瘤和瘤微环境在口腔癌中发生的变化,并获得了对免疫疗法的耐药性
Yoh-Ichiro Iwasa1, Tomoyuki Nakajima2, Kentaro Hori1
1Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
Biomolecules
|December 23, 2023
概括
在头角状细胞癌 (HNSCC) 中对抗编程死亡-1 (PD-1) 治疗的获得性耐药性涉及动态瘤和微环境变化. 瘤中的表观遗传修饰似乎阻碍了抗PD-1免疫反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 反编程死亡-1 (PD-1) 疗法为头部和部状细胞癌 (HNSCC) 提供了改善的结果.
- 获得对PD-1抑制剂的耐药性是一个重大的临床挑战,导致疾病进展,尽管最初的反应.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529


